Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2033
2.3 Market Size & Forecast, By Segmentation, 2022–2033
2.3.1 Market Size By Type
2.3.2 Market Size By Distribution Channel
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Pricing Analysis & Forecast
4.1.1 Overview
4.1.2 Average Treatment Cost per Patient by Region (USD)
4.1.3 Price Benchmarking by Key Pharmaceutical Companies
4.1.4 Cost Comparison: Erleada vs. Other mCRPC Therapies (e.g., Xtandi, Zytiga)
4.1.5 Forecasted Price Trends: Impact of Patent Expiry and Biosimilars
4.2 Regulatory & Approval Landscape
4.2.1 Overview
4.2.2 FDA & EMA Approval Timelines and Regulatory Success Rates
4.2.3 Orphan Drug Designation Statistics (%)
4.2.4 Regional Regulatory Guidelines and Reimbursement Policies
4.2.5 Ongoing Clinical Trial Approval Rates
4.3 Clinical & Pipeline Metrics
4.3.1 Overview
4.3.2 Number of Ongoing Clinical Trials by Phase (I, II, III)
4.3.3 Patient Enrollment Statistics by Region
4.3.4 Treatment Response Rates (%) and Progression-Free Survival Data
4.3.5 Comparative Efficacy Metrics vs. Competitor Drugs
5. Erleada Market Segmental Analysis & Forecast, By Type, 2022–2033, Value (USD Million)
5.1 Introduction
5.2 Branded
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022–2033
5.3 Generic
6. Erleada Market Segmental Analysis & Forecast, By Distribution Channel, 2022–2033, Value (USD Million)
6.1 Introduction
6.2 Hospital Pharmacies
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022–2033
6.3 Retail Pharmacies
6.4 Others
7. Erleada Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Million)
7.1 Introduction
7.2 North America
7.2.1 Key Trends
7.2.2 Erleada Market Size & Forecast, By Type, 2022–2033
7.2.3 Erleada Market Size & Forecast, By Distribution Channel, 2022–2033
7.2.4 Erleada Market Size & Forecast, By Country, 2022–2033
7.2.4.1 USA
7.2.4.2 Canada
7.3 Europe
7.3.1 Key Trends
7.3.2 Erleada Market Size & Forecast, By Type, 2022–2033
7.3.3 Erleada Market Size & Forecast, By Distribution Channel, 2022–2033
7.3.4 Erleada Market Size & Forecast, By Country, 2022–2033
7.3.4.1 Germany
7.3.4.2 UK
7.3.4.3 France
7.3.4.4 Italy
7.3.4.5 Spain
7.3.4.6 Russia
7.3.4.7 Poland
7.3.4.8 Rest of Europe
7.4 Asia-Pacific
7.4.1 Key Trends
7.4.2 Erleada Market Size & Forecast, By Type, 2022–2033
7.4.3 Erleada Market Size & Forecast, By Distribution Channel, 2022–2033
7.4.4 Erleada Market Size & Forecast, By Country, 2022–2033
7.4.4.1 China
7.4.4.2 India
7.4.4.3 Japan
7.4.4.4 South Korea
7.4.4.5 Australia
7.4.4.6 ASEAN Countries
7.4.4.7 Rest of Asia-Pacific
7.5 Latin America
7.5.1 Key Trends
7.5.2 Erleada Market Size & Forecast, By Type, 2022–2033
7.5.3 Erleada Market Size & Forecast, By Distribution Channel, 2022–2033
7.5.4 Erleada Market Size & Forecast, By Country, 2022–2033
7.5.4.1 Brazil
7.5.4.2 Argentina
7.5.4.3 Mexico
7.5.4.4 Colombia
7.5.4.5 Rest of Latin America
7.6 Middle East & Africa
7.6.1 Key Trends
7.6.2 Erleada Market Size & Forecast, By Type, 2022–2033
7.6.3 Erleada Market Size & Forecast, By Distribution Channel, 2022–2033
7.6.4 Erleada Market Size & Forecast, By Country, 2022–2033
7.6.4.1 UAE
7.6.4.2 Saudi Arabia
7.6.4.3 Qatar
7.6.4.4 Egypt
7.6.4.5 South Africa
7.6.4.6 Rest of Middle East & Africa
8. Competitive Landscape
8.1 Key Players' Positioning
8.2 Competitive Developments
8.2.1 Key Strategies Adopted (%), By Key Players, 2024
8.2.2 Year-Wise Strategies & Development, 2021 – 2025
8.2.3 Number Of Strategies Adopted By Key Players, 2024
8.3 Market Share Analysis, 2024
8.4 Product/Service & Application Benchmarking
8.4.1 Product/Service Specifications & Features By Key Players
8.4.2 Product/Service Heatmap By Key Players
8.4.3 Application Heatmap By Key Players
8.5 Industry Start-Up & Innovation Landscape
8.6 Key Company Profiles
8.6.1 Janssen Biotech, Inc.
8.6.1.1 Company Overview & Snapshot
8.6.1.2 Product/Service Portfolio
8.6.1.3 Key Company Financials
8.6.1.4 SWOT Analysis
8.6.2 Zydus Lifesciences Ltd.
8.6.3 Pfizer Inc.
8.6.4 Astellas Pharma Inc.
8.6.5 Bayer AG
8.6.6 Novartis AG
8.6.7 Merck & Co., Inc.
8.6.8 AstraZeneca PLC
8.6.9 Sanofi S.A.
8.6.10 Bristol‑Myers Squibb Company
8.6.11 Amgen Inc.
8.6.12 Eli Lilly and Company
8.6.13 GlaxoSmithKline plc
8.6.14 Takeda Pharmaceutical Company Limited
8.6.15 AbbVie Inc.
8.6.16 Ferring Pharmaceuticals
8.6.17 MacroGenics, Inc.
8.6.18 Candel Therapeutics
8.6.19 Myovant Sciences
8.6.20 Meissa Vaccines, Inc.
9. Analyst Recommendations
9.1 SNS Insider Opportunity Map
9.2 Industry Low-Hanging Fruit Assessment
9.3 Market Entry & Growth Strategy
9.4 Analyst Viewpoint & Suggestions On Market Growth
10. Assumptions
11. Disclaimer
12. Appendix
12.1 List Of Tables
12.2 List Of Figures
